Related Experiment Video
Updated: Mar 19, 2026
06:11
Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
Published on: May 17, 2024
1.3K
Gestational diabetes mellitus: does an effective prevention strategy exist?
Rochan Agha-Jaffar1, Nick Oliver1, Desmond Johnston1
1Division of Diabetes, Endocrinology and Metabolism, G3 Medical School Building, Imperial College London, Norfolk Place, London, W2 1PG, UK.
Nature Reviews. Endocrinology
|June 25, 2016
Summary
Preventing gestational diabetes mellitus (GDM) is crucial for maternal and infant health. Current lifestyle, dietary, and pharmacological interventions show limited success, necessitating further research for effective population-level strategies.
Area of Science:
- Obstetrics and Gynecology
- Endocrinology
- Public Health
Background:
- Gestational diabetes mellitus (GDM) incidence is rising globally.
- Preventing GDM offers benefits including reduced adverse pregnancy outcomes and long-term sequelae.
- Effective prevention strategies are needed to decrease healthcare burden.
Purpose of the Study:
- To review evidence on lifestyle modifications for GDM prevention.
- To evaluate dietary supplementation and pharmacological approaches for GDM prevention.
- To identify effective, implementable population-level GDM prevention strategies.
Main Methods:
- Systematic review of randomized controlled trials and population studies.
- Analysis of lifestyle interventions (diet, physical activity).
- Evaluation of dietary supplements (probiotics, myoinositol) and pharmacological agents (metformin).
Main Results:
- Population-level lifestyle interventions show no improvement in GDM risk.
- Physical activity interventions yield conflicting results and show low compliance in obese pregnant women.
- Probiotics and myoinositol show potential but require further confirmation; metformin is ineffective in some at-risk groups.
Conclusions:
- Heterogeneity in trials complicates generalized recommendations for GDM prevention.
- Current interventions have limited efficacy, particularly for population-level implementation.
- Further research is essential to develop easily implementable and effective GDM prevention strategies.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
01:20Pathophysiology of Diabetes
4.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.2K
01:15Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
871
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
871
01:15Diabetes: Management and Pharmacotherapy
1.3K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
934
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934